Diametric Capital LP Grows Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Diametric Capital LP grew its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 39.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 94,737 shares of the company’s stock after buying an additional 26,881 shares during the quarter. Delcath Systems accounts for about 0.8% of Diametric Capital LP’s portfolio, making the stock its 27th largest holding. Diametric Capital LP owned about 0.30% of Delcath Systems worth $1,141,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of DCTH. Point72 Asia Singapore Pte. Ltd. acquired a new position in Delcath Systems in the third quarter valued at approximately $102,000. Polar Asset Management Partners Inc. purchased a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $1,594,000. State Street Corp boosted its holdings in Delcath Systems by 12.4% during the third quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after buying an additional 9,400 shares in the last quarter. Jane Street Group LLC acquired a new stake in Delcath Systems during the third quarter valued at $110,000. Finally, Barclays PLC purchased a new position in Delcath Systems in the third quarter valued at $104,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Down 3.2 %

DCTH stock opened at $12.73 on Tuesday. Delcath Systems, Inc. has a 52 week low of $4.26 and a 52 week high of $16.97. The firm has a 50-day simple moving average of $14.56 and a 200-day simple moving average of $12.07. The stock has a market capitalization of $425.22 million, a P/E ratio of -9.43 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same period in the previous year, the company earned ($0.48) EPS. On average, analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on DCTH shares. Craig Hallum increased their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. HC Wainwright increased their price target on Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.